Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity

V. Pengo, T. Brocco, A. Biasiolo, P. Rampazzo, P. Carraro, R. Zamarchi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Prothrombin time (PT) is routinely used to monitor oral anticoagulant treatment in patients with the antiphospholipid antibody syndrome (APS). The fact that PT is a phospholipid (PL)-dependent coagulation test raises the possibility that lupus anticoagulant (LA) might interfere with this test, thus complicating the control of anticoagulant treatment. The effect of 6 affinity-purified preparations of anti- (a)β2-glycoprotein I (GPI) antibodies with LA activity on the PT was tested. Instead of prolonging PT as expected, the aβ2-GPI antibodies reduced the PT of both normal plasma and anticoagulated plasma by a mean of 2.4 seconds and 5.6 seconds, respectively. This effect was also observed using other 5 commercially available preparations of thromboplastin. The aβ2-GPI-mediated reduction in PT was dose-dependent and was lost upon removal of β2-GPI. The failure of aβ2-GPI antibodies to express LA activity in PT was found to depend on the fact that calcium ions were added together with PL at the beginning of the assay. In fact, modification of the standard diluted Russell viper venom time (dRVVT) test by adding calcium ions together with PL resulted in a loss of aβ2-GPI anticoagulant activity. The procoagulant effect was not as evident in an assay that used stimulated monocytes as a source of thromboplastin. These results show that aβ2-GPI antibodies exhibit an 'in vitro' procoagulant effect in PT and an anticoagulant effect in dRVVT only when the interaction with their antigen and PL occurs in the absence of calcium ions.

Original languageEnglish
Pages (from-to)3814-3819
Number of pages6
JournalBlood
Volume94
Issue number11
Publication statusPublished - Dec 1 1999

Fingerprint

Lupus Coagulation Inhibitor
Prothrombin Time
Prothrombin
Glycoproteins
Antibodies
Anticoagulants
Phospholipids
Viper Venoms
Thromboplastin
Ions
Calcium
Assays
Plasmas
Antiphospholipid Antibodies
Coagulation
Antiphospholipid Syndrome
Monocytes
Antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Pengo, V., Brocco, T., Biasiolo, A., Rampazzo, P., Carraro, P., & Zamarchi, R. (1999). Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity. Blood, 94(11), 3814-3819.

Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity. / Pengo, V.; Brocco, T.; Biasiolo, A.; Rampazzo, P.; Carraro, P.; Zamarchi, R.

In: Blood, Vol. 94, No. 11, 01.12.1999, p. 3814-3819.

Research output: Contribution to journalArticle

Pengo, V, Brocco, T, Biasiolo, A, Rampazzo, P, Carraro, P & Zamarchi, R 1999, 'Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity', Blood, vol. 94, no. 11, pp. 3814-3819.
Pengo V, Brocco T, Biasiolo A, Rampazzo P, Carraro P, Zamarchi R. Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity. Blood. 1999 Dec 1;94(11):3814-3819.
Pengo, V. ; Brocco, T. ; Biasiolo, A. ; Rampazzo, P. ; Carraro, P. ; Zamarchi, R. / Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity. In: Blood. 1999 ; Vol. 94, No. 11. pp. 3814-3819.
@article{e01bd266273e46be952eb140a6a05118,
title = "Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity",
abstract = "Prothrombin time (PT) is routinely used to monitor oral anticoagulant treatment in patients with the antiphospholipid antibody syndrome (APS). The fact that PT is a phospholipid (PL)-dependent coagulation test raises the possibility that lupus anticoagulant (LA) might interfere with this test, thus complicating the control of anticoagulant treatment. The effect of 6 affinity-purified preparations of anti- (a)β2-glycoprotein I (GPI) antibodies with LA activity on the PT was tested. Instead of prolonging PT as expected, the aβ2-GPI antibodies reduced the PT of both normal plasma and anticoagulated plasma by a mean of 2.4 seconds and 5.6 seconds, respectively. This effect was also observed using other 5 commercially available preparations of thromboplastin. The aβ2-GPI-mediated reduction in PT was dose-dependent and was lost upon removal of β2-GPI. The failure of aβ2-GPI antibodies to express LA activity in PT was found to depend on the fact that calcium ions were added together with PL at the beginning of the assay. In fact, modification of the standard diluted Russell viper venom time (dRVVT) test by adding calcium ions together with PL resulted in a loss of aβ2-GPI anticoagulant activity. The procoagulant effect was not as evident in an assay that used stimulated monocytes as a source of thromboplastin. These results show that aβ2-GPI antibodies exhibit an 'in vitro' procoagulant effect in PT and an anticoagulant effect in dRVVT only when the interaction with their antigen and PL occurs in the absence of calcium ions.",
author = "V. Pengo and T. Brocco and A. Biasiolo and P. Rampazzo and P. Carraro and R. Zamarchi",
year = "1999",
month = "12",
day = "1",
language = "English",
volume = "94",
pages = "3814--3819",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Procoagulant effect of anti-β2-glycoprotein I antibodies with lupus anticoagulant activity

AU - Pengo, V.

AU - Brocco, T.

AU - Biasiolo, A.

AU - Rampazzo, P.

AU - Carraro, P.

AU - Zamarchi, R.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Prothrombin time (PT) is routinely used to monitor oral anticoagulant treatment in patients with the antiphospholipid antibody syndrome (APS). The fact that PT is a phospholipid (PL)-dependent coagulation test raises the possibility that lupus anticoagulant (LA) might interfere with this test, thus complicating the control of anticoagulant treatment. The effect of 6 affinity-purified preparations of anti- (a)β2-glycoprotein I (GPI) antibodies with LA activity on the PT was tested. Instead of prolonging PT as expected, the aβ2-GPI antibodies reduced the PT of both normal plasma and anticoagulated plasma by a mean of 2.4 seconds and 5.6 seconds, respectively. This effect was also observed using other 5 commercially available preparations of thromboplastin. The aβ2-GPI-mediated reduction in PT was dose-dependent and was lost upon removal of β2-GPI. The failure of aβ2-GPI antibodies to express LA activity in PT was found to depend on the fact that calcium ions were added together with PL at the beginning of the assay. In fact, modification of the standard diluted Russell viper venom time (dRVVT) test by adding calcium ions together with PL resulted in a loss of aβ2-GPI anticoagulant activity. The procoagulant effect was not as evident in an assay that used stimulated monocytes as a source of thromboplastin. These results show that aβ2-GPI antibodies exhibit an 'in vitro' procoagulant effect in PT and an anticoagulant effect in dRVVT only when the interaction with their antigen and PL occurs in the absence of calcium ions.

AB - Prothrombin time (PT) is routinely used to monitor oral anticoagulant treatment in patients with the antiphospholipid antibody syndrome (APS). The fact that PT is a phospholipid (PL)-dependent coagulation test raises the possibility that lupus anticoagulant (LA) might interfere with this test, thus complicating the control of anticoagulant treatment. The effect of 6 affinity-purified preparations of anti- (a)β2-glycoprotein I (GPI) antibodies with LA activity on the PT was tested. Instead of prolonging PT as expected, the aβ2-GPI antibodies reduced the PT of both normal plasma and anticoagulated plasma by a mean of 2.4 seconds and 5.6 seconds, respectively. This effect was also observed using other 5 commercially available preparations of thromboplastin. The aβ2-GPI-mediated reduction in PT was dose-dependent and was lost upon removal of β2-GPI. The failure of aβ2-GPI antibodies to express LA activity in PT was found to depend on the fact that calcium ions were added together with PL at the beginning of the assay. In fact, modification of the standard diluted Russell viper venom time (dRVVT) test by adding calcium ions together with PL resulted in a loss of aβ2-GPI anticoagulant activity. The procoagulant effect was not as evident in an assay that used stimulated monocytes as a source of thromboplastin. These results show that aβ2-GPI antibodies exhibit an 'in vitro' procoagulant effect in PT and an anticoagulant effect in dRVVT only when the interaction with their antigen and PL occurs in the absence of calcium ions.

UR - http://www.scopus.com/inward/record.url?scp=0033485643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033485643&partnerID=8YFLogxK

M3 - Article

C2 - 10572096

AN - SCOPUS:0033485643

VL - 94

SP - 3814

EP - 3819

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -